Back to Search Start Over

Subclinical acromegaly: to treat or not to treat?

Authors :
Shimon I
Adnan Z
Hirsch D
Duskin-Bitan H
Akirov A
Source :
Endocrine journal [Endocr J] 2022 Nov 28; Vol. 69 (11), pp. 1323-1328. Date of Electronic Publication: 2022 Jun 22.
Publication Year :
2022

Abstract

Patients with acromegaly usually present with the classical signs of acromegaly, whereas patients without the specific signs or symptoms are rarely diagnosed. This unique entity can be named "subclinical acromegaly". This was a retrospective study. Our study group consisted of 6 patients (4 females) with incidentally diagnosed acromegaly, most following head MRI for unrelated reasons and without the specific signs of acromegaly. Mean age at diagnosis was 48.8 ± 19.2 years. Baseline IGF-1 ranged between 1.3-2.0 × upper limit of normal (ULN). MRI depicted a pituitary microadenoma in 5 patients, and one patient presented with a 12 mm intra-sellar macroadenoma. Mean calculated SAGIT clinical score was 4.8. Three patients underwent trans-sphenoidal resection; two achieved hormonal remission and one improved but did not normalize IGF-1 following surgery. Four patients (including one following surgery) were given somatostatin analogs, and three normalized IGF-1. Several patients improved clinically following treatment, reporting improvement in snoring, hypertension, or weight loss, and pituitary adenoma decreased in size in 2 patients that responded to medical treatment. We report a series of 6 patients with very mild and subclinical acromegaly. It is uncertain whether all such patients will gain clinical benefit from treatment, but most experienced clinical improvement due to treatment.

Details

Language :
English
ISSN :
1348-4540
Volume :
69
Issue :
11
Database :
MEDLINE
Journal :
Endocrine journal
Publication Type :
Academic Journal
Accession number :
35732439
Full Text :
https://doi.org/10.1507/endocrj.EJ22-0066